Correlation between serum marker variations and pulmonary hypertension secondary to chronic obstructive pulmonary disease.
- Author:
Xinming XIE
1
;
Xiaochuang WANG
;
Yonghong ZHANG
;
Dong HAN
;
Shaojun LI
;
Manxiang LI
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Biomarkers; blood; Blood Pressure; C-Reactive Protein; metabolism; Endothelin-1; blood; Female; Humans; Hypertension, Pulmonary; blood; complications; physiopathology; Interleukin-6; blood; Male; Natriuretic Peptide, Brain; blood; Pulmonary Disease, Chronic Obstructive; blood; complications; physiopathology
- From: Journal of Southern Medical University 2013;33(10):1458-1462
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo examine the correlation of the changes in the serum markers (C-reactive protein, endothelin-1, interleukin-6, and brain natriuretic peptide) with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension secondary to COPD.
METHODSA total of 174 COPD patients with acute exacerbation, admitted between February 2011 and February, 2013, were enrolled in this study, with 43 volunteers with normal pulmonary functions as controls. Pulmonary arterial pressure was determined by Doppler echocardiograph, and the severities (mild, moderate and severe) of PH secondary to COPD was evaluated. The levels of serum markers were determined using ELISA kits.
RESULTSThe levels of serum markers in patients with COPD was significantly elevated compared with those of the control subjects (P<0.05), and further increased in patients with pulmonary hypertension secondary to COPD (P<0.05). A positive correlation was found between these serum markers and pulmonary artery pressure in COPD patients with mild and moderate pulmonary hypertension. In patients with severe pulmonary hypertension, only the serum level of brain natriuretic peptide continued to increase with pulmonary artery pressure (P<0.05), and the other markers did not further increase.
CONCLUSIONSEarly and combined examination of these serum markers in patients with COPD can help to identify pulmonary hypertension in early stage and estimate the severity of pulmonary hypertension. Hemodynamic monitoring of the changes of these serum markers can be of important clinical value in the treatment of pulmonary hypertension secondary to COPD and in evaluation of the prognosis of COPD.